Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease

2011/05/22 by Nina Raju, Magdalena Sobieraj-Teague, Magdalena Sobieraj‐Teague +5 · 27 citations
Medicine · #Antiplatelet Therapy and Cardiovascular Diseases #Inflammatory mediators and NSAID effects #Lipoproteins and Cardiovascular Health

paper · pdf · doi:10.1016/j.amjmed.2011.01.018

Cited by

• Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study
• Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
• Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. [europepmc]
• The impact of antiplatelet medication on hand and wrist surgery. [europepmc]
• How confidence intervals become confusion intervals. [europepmc]
• Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. [europepmc]
• A 16-month community-based intervention to increase aspirin use for primary prevention of cardiovascular disease. [europepmc]
• Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. [europepmc]
• A systematic review of aspirin in primary prevention: is it time for a new approach? [europepmc]
• Use of medications and lifestyles of hypertensive patients with high risk of cardiovascular disease in rural China. [europepmc]
• Aspirin for primary prevention of cardiovascular disease. [europepmc]
• Proteome-wide prediction of targets for aspirin: new insight into the molecular mechanism of aspirin. [europepmc]
• Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. [europepmc]
• Neutrophil-Derived Cytosolic PLA2α Contributes to Bacterial-Induced Neutrophil Transepithelial Migration. [europepmc]
• A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. [europepmc]
• Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2018. [europepmc]
• Aspirin and diabetes mellitus in primary prevention: the Endless Conundrum. [europepmc]
• Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. [europepmc]
• Frequency of Intracranial Hemorrhage With Low-Dose Aspirin in Individuals Without Symptomatic Cardiovascular Disease: A Systematic Review and Meta-analysis. [europepmc]
• The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy. [europepmc]
• The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis. [europepmc]
• Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. [europepmc]
• All-cause mortality following low-dose aspirin treatment for patients with high cardiovascular risk in remote Australian Aboriginal communities: an observational study. [europepmc]
• Prevention of stroke in people living with HIV. [europepmc]
• Efficacy of Teprenone for Prevention of NSAID-Induced Gastrointestinal Injury: A Systematic Review and Meta-Analysis. [europepmc]
• Caloric Restriction Mimetics in Nutrition and Clinical Trials. [europepmc]
• Neutrophil-Mediated Immunopathology and Matrix Metalloproteinases in Central Nervous System - Tuberculosis. [europepmc]